On August 10, ZAI LAB rose 6.45% in regular trading, trading at 17.88 HKD/share, with turnover of approximately 46.85 million HKD. The stock continued its upward momentum following Q2 earnings released on August 6 and multiple positive pipeline developments.

The company reported Q2 total revenue of $106.3 million, with net product revenue of $105.8 million, up 11% quarter-over-quarter and exceeding market expectations by approximately $2.5 million. The beat was driven by stable performance from Zejula and continued sales growth of Efgartigimod. Citibank issued a report noting that the sequential improvement in product revenue increases confidence that ZAI LAB's China business can stabilize in H2 and resume significant growth next year per management guidance.

Additionally, the company's commercial portfolio continues to expand with the recent NMPA approval of Tivdak for recurrent or metastatic cervical cancer patients, as well as the launch and volume ramp of Kaijiele, an innovative schizophrenia treatment that has already reached patients across more than 30 cities and nearly 50 hospitals nationwide.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)